Pro-immunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy [PDA30364 treated with MEKi, CD40, in vivo]

ABSTRACT: Pro-immunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy [PDA30364 treated with MEKi, CD40, in vivo]

PROVIDER: PRJNA602881 | ENA |

REPOSITORIES: ENA